Company Filing History:
Years Active: 1997-1998
Title: Innovations of Keith Brian Wheeler in Oral Rehydration Solutions
Introduction
Keith Brian Wheeler is an accomplished inventor based in Dublin, OH (US). He has made significant contributions to the field of oral rehydration solutions, particularly in relation to the treatment of diarrhea associated with Clostridium difficile infections. With a total of 2 patents, his work focuses on innovative approaches to enhance recovery from dehydration.
Latest Patents
Wheeler's latest patents include an oral rehydration solution containing indigestible oligosaccharides. This solution is designed to address diarrhea-related dehydration, which requires fluid and electrolyte replacement. The primary cause of antibiotic-associated diarrhea has been identified as Clostridium difficile. The indigenous microflora of a healthy individual typically suppresses the presence of C. difficile. However, disruptions to this microflora, often due to antibiotic treatment, can lead to an overgrowth of C. difficile, resulting in diarrhea and colitis. Wheeler's invention aims to normalize the microflora to inhibit C. difficile relapse, utilizing indigestible oligosaccharides that have shown effectiveness in preventing infections.
Career Highlights
Wheeler is currently employed at Abbott Laboratories Corporation, where he continues to innovate in the field of healthcare solutions. His work has been instrumental in developing therapies that address significant health challenges related to gastrointestinal infections.
Collaborations
Throughout his career, Wheeler has collaborated with notable colleagues, including Bryan W. Wolf and Keith A. Garleb. These partnerships have contributed to the advancement of research and development in the area of oral rehydration solutions.
Conclusion
Keith Brian Wheeler's contributions to the field of oral rehydration solutions highlight the importance of innovative approaches in treating gastrointestinal infections. His work not only addresses immediate health concerns but also aims to improve long-term outcomes for patients suffering from antibiotic-associated diarrhea.